For the entire treatment period , a higher proportion of patients in the PC/gefitinib arm versus gefitinib experienced possibly drug-related grade @-@ treatment-emergent adverse events ( @ of @ -LSB- @ % -RSB- versus @ of @ -LSB- @ % -RSB- ; p = @ ) .